Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Development of experimental autoimmune encephalomyelitis (EAE) in mice requires vitamin D and the vitamin D receptor.
Brain Volume Loss during the First Year of Interferon-Beta Treatment: Baseline Inflammation and Tissue-Specific Volume Dynamics.
Glatiramer acetate in the treatment of multiple sclerosis
Kif1b is essential for mRNA localization in oligodendrocytes and development of myelinated axons.
Glatiramer acetate ameliorates experimental autoimmune neuritis.
Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
Synthetic Biologics Announces Issuance of U.S. Patent Adding Another Layer of Protection for the Use of Oral Estriol Candidate, Trimesta™, for Multiple Sclerosis
Emotional Change-Associated T Cell Mobilization at the Early Stage of a Mouse Model of Multiple Sclerosis.
Translating Fatigue to Human Performance.
Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis; Acquires Bayer’s Hematologic Oncology Portfolio; First of Two Alemtuzumab MS Phase 3 Trials Completes Enrollment
Recurrent brainstem lesions mimicking infarctions in an elderly patient with neuromyelitis optica spectrum disorder.
Tcelna® (imilecleucel-T)
Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies: A Comparative Study.
Urodynamic and physiologic patterns associated with the common causes of neurogenic bladder in adults.
Fingolimod Impedes Schwann Cell-Mediated Myelination: Implications for the Treatment of Immune Neuropathies?Effect of Fingolimod on Schwann Cells.
Receptos reports third quarter 2013 financial results
Gait Mechanics are Different between Healthy Controls and Patients with Multiple Sclerosis.
Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system.
Change in the clinical development program for laquinimod
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
Spin-offs: Meet the structure specialists
Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple scl
4th Biannual NeuroUnit Biomarkers for Inflammation and Neurodegeneration Symposium on Biomarkers in Neurodegenerative Disease
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.

Pages